P
AXSM icon

Pitcairn’s Axsome Therapeutics AXSM Stock Holding History

Pitcairn’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,106
Closed -$742K – 51
2025
Q3 		$742K Sell
6,106
-2,407
-28% -$271K 0.06% 267
2025
Q2 		$889K Buy
8,513
+4,242
+99% +$449K 0.06% 284
2025
Q1 		$498K Sell
4,271
-291
-6% -$33.2K 0.03% 427
2024
Q4 		$386K Buy
4,562
+148
+3% +$13.6K 0.02% 506
2024
Q3 		$397K Sell
4,414
-561
-11% -$49K 0.02% 514
2024
Q2 		$400K Buy
4,975
+301
+6% +$22.3K 0.02% 506
2024
Q1 		$373K Sell
4,674
-290
-6% -$24.3K 0.02% 515
2023
Q4 		$395K Sell
4,964
-138
-3% -$9.23K 0.03% 461
2023
Q3 		$357K Buy
5,102
+67
+1% +$5.01K 0.03% 449
2023
Q2 		$362K Sell
5,035
-16
-0.3% -$1.18K 0.03% 463
2023
Q1 		$312K Buy
5,051
+59
+1% +$3.88K 0.03% 480
2022
Q4 		$385K Buy
4,992
+498
+11% +$29.8K 0.04% 386
2022
Q3 		$201K Buy
+4,494
New +$225K 0.02% 550
2021
Q4 		– Sell
-7,874
Closed -$260K – 627
2021
Q3 		$260K Buy
7,874
+3,077
+64% +$120K 0.02% 541
2021
Q2 		$324K Buy
4,797
+322
+7% +$19.3K 0.02% 481
2021
Q1 		$253K Buy
+4,475
New +$315K 0.02% 530

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pitcairn's AXSM Position: Q4 2025 in Review

Pitcairn sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 6,106 shares — an estimated $742K sold.

Pitcairn first reported a position in AXSM in Q1 2021 and held it in 16 quarters. The position peaked at $889K in Q2 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Pitcairn reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Pitcairn sold 6,106 Axsome Therapeutics shares in Q4 2025, an estimated $742K.
  • Pitcairn first reported a position in Axsome Therapeutics in Q1 2021 and held it in 16 quarters.
  • Pitcairn's Axsome Therapeutics position peaked at $889K in Q2 2025.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.